MCMegan Eb Clowse

Megan Eb Clowse

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Megan Eb Clowse has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Astrid van Tubergen

    Department of Rheumatology, Maastricht University Medical Centre+, Maastricht, the Netherlands; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands

    1 shared publication
  • Caroline Hwang

    Keck Hospital of USC, Los Angeles, California, USA

    1 shared publication
  • Frauke Förger

    Department of Rheumatology and Immunology and Allergology, Inselspital, University Hospital and University of Bern, Bern, Switzerland

    1 shared publication
  • Jeff Simpson

    UCB Pharma, Raleigh, North Carolina, USA

    1 shared publication
  • John Thorp

    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

    1 shared publication
  • Laura Shaughnessy

    UCB Pharma, Raleigh, North Carolina, USA

    1 shared publication

Latest Publications

  • Open Access

    Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study

    by Megan Eb Clowse, Frauke Förger, Caroline Hwang, John Thorp, Radboud Jem Dolhain, Astrid van Tubergen, Laura Shaughnessy, Jeff Simpson, Marie Teil, Nathalie Toublanc, et al.

    Background Women with chronic inflammatory diseases face uncertainty regarding the safety of biologics during breast feeding. CRADLE was the first industry-sponsored study to evaluate certolizumab pegol (CZP) concentrations in human breast milk and estimate average daily infant dose (ADID) of maternal CZP. Methods CRADLE (NCT02154425) was a pharmacokinetic study of lactating mothers receiving CZP. After ≥3 CZP doses, breast milk samples were collected across one dosing period (14 days for 200 mg every 2 weeks [Q2W]; 28 days for 400 mg every 4 weeks [Q4W]). Optimal analytical methods were developed to determine CZP and polyethylene glycol (PEG) levels in breast milk. ADID and relative infant dose (RID) were estimated. Safety events in mothers and infants were assessed. Results 19 CZP-treated mothers were screened; 17 entered the sampling period: 16 on 200 mg Q2W, 1 on 400 mg Q4W. 77/137 (56%) breast milk samples had no measurable CZP. For 4/17 mothers, all samples were below the lower limit of quantification (LLOQ). Estimated ADID was 0–0.0104 mg/kg/day; median RID: 0.15%. PEG was undetectable in 134/137 samples (results could not be determined in three samples). Infants of CZP-exposed mothers had a safety profile consistent with that of unexposed similar-age infants. Conclusion When quantifiable, CZP concentrations were Trial registration number NCT02154425; Results.